MRSN Mersana Therapeutics: Company Short-Term Debts

Symbol and logo of brand Mersana (MRSN)

Mersana Therapeutics (MRSN) is mitigating risks by adapting its ADC platform for various tumors and establishing global partnerships. The current volume of short-term loans demonstrates financial stability, where the value of 0.00 captures this metric. The technology for the targeted delivery of high-dose cytostatics minimizes toxicity. Environmental policy relies on digitalization and strict control over biohazardous waste disposal in laboratories.

MRSN mersana.com Company Short-Term Loans and Borrowings (07/04/2022 - 01/17/2026)

MRSN (Mersana Therapeutics Inc): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Price Mersana|MRSN - Consensus Target
- company stock capitalization data:
Market Capitalization Mersana Therapeutics, Inc.|MRSN - Total Enterprise Value
- business book valuation details:
Net Assets per Single Share Mersana Therapeutics|MRSN - Accounting Value of Company|Market Cap to Net Assets Ratio mersana.com|MRSN - Aggregate Asset Value
- debt and liquidity details:
Total Debt to Equity Ratio Mersana Therapeutics|MRSN - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Mersana|MRSN - Company Cumulative Debt|Debt to Book Capitalization Ratio Mersana Therapeutics, Inc.|MRSN - Company Long-Term Liabilities|Company Short-Term Debts Mersana Therapeutics|Quick Liquidity mersana.com
- earnings and multiples data:
MRSN - Company Profit
Basic company analysis:MRSN - mersana.com
Flagship merchandise of Mersana

Short-term debts measure the volume of obligations with a maturity of up to one year, reflecting current liquidity and the business's ability to cover operating expenses without emergency capital raises. By analyzing changes in short-term liabilities on GURU.Markets, a Mersana Therapeutics (MRSN) investor can assess the company's financial stability in the face of binary risks associated with clinical trials of specialized drugs, where any spikes in debt signal a critical increase in the debt load.

Competitor analysis

Merus - Company Short-Term Debts|Immutep Ltd (IMMP) - Company Current Liabilities|ANIX: Company Short-Term Debts|Short-Term Debt Atossa Pharma (ATOS)|Company Short-Term Debt Context Therapeutics Inc|BCTX: Company Short-Term Loans and Borrowings|Company Current Liabilities EPIX (ESSA Pharma Inc.)|QTI (QT Imaging Holdings) - Company Short-Term Loans and Borrowings